Nuzenio

Adc Subcutaneous Formulation

Adc Subcutaneous Formulation news intelligence with latest source-attributed stories, timeline, related explainers, connected entities, source diversity, and FAQ.

topic 6 latest news signals 6 publisher sources 100/100 entity strength

Latest news

HALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance - TradingViewTradingView · Fri, 07 Aug 2026 22:20:49 GMTAlteogen returns to profit as Keytruda SC sales and platform deals surge - CHOSUNBIZ - ChosunbizChosunbiz · Fri, 07 Aug 2026 02:00:00 GMTPathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC - Business WireBusiness Wire · Tue, 04 Aug 2026 00:00:00 GMTHuonslab patents ADC injection platform - Korea JoongAng DailyKorea JoongAng Daily · Mon, 27 Jul 2026 07:28:54 GMTHuonslab Secures Patent for ADC Subcutaneous Formulation Incorporating ‘HyDIFFUZE™’ Platform - Yahoo FinanceYahoo Finance · Mon, 27 Jul 2026 07:00:00 GMTHuonslab targets subcutaneous ADC market with new patent - koreabiomed.comkoreabiomed.com · Mon, 27 Jul 2026 04:31:11 GMT

Timeline

Fri, 07 Aug 2026 22:20:49 GMTHALO Q2 Deep Dive: Royalty Diversification and New Pipeline Drive Upgraded Guidance - TradingView
Fri, 07 Aug 2026 02:00:00 GMTAlteogen returns to profit as Keytruda SC sales and platform deals surge - CHOSUNBIZ - Chosunbiz
Tue, 04 Aug 2026 00:00:00 GMTPathos AI Enters Global Licensing Agreement with Alphamab Oncology on JSKN016, a First-in-Class TROP2/HER3 Bispecific ADC - Business Wire
Mon, 27 Jul 2026 07:28:54 GMTHuonslab patents ADC injection platform - Korea JoongAng Daily
Mon, 27 Jul 2026 07:00:00 GMTHuonslab Secures Patent for ADC Subcutaneous Formulation Incorporating ‘HyDIFFUZE™’ Platform - Yahoo Finance
Mon, 27 Jul 2026 04:31:11 GMTHuonslab targets subcutaneous ADC market with new patent - koreabiomed.com

FAQ

What does this page track?

Latest RSS headlines, source names, timestamps, related explainers, connected entities, and timeline signals for Adc Subcutaneous Formulation.

Why might this page be noindex?

Nuzenio only indexes entity pages after enough useful source-attributed coverage and source diversity exists.

Where should readers verify facts?

Open the original publisher links from each story for full reporting, quotes, figures, images, corrections, and updates.

Source diversity

6 distinct publisher/source names are currently connected to this entity page.